Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2026-02-18 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Avacta to Participate in Conference March 2026
Regulatory Filings Classification · 98% confidence The document is a short press release (under 5,000 characters) announcing that Avacta Group PLC's executive management team will participate in an upcoming investor conference. It does not contain the presentation materials themselves, but rather informs the public of the event and where to find future information. Under the 'Menu vs Meal' rule, this is classified as a general regulatory announcement/press release.
2026-02-18 English
Appointment of CSO
Board/Management Information Classification · 100% confidence The document is an official announcement from Avacta Group PLC regarding the appointment of a new Chief Scientific Officer (Francis Wilson) and the departure of the former CSO. This type of corporate announcement concerning changes in senior management falls directly under the 'Board/Management Information' category.
2026-02-09 English
Faridoxorubicin Program Clinical Updates
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Avacta Group PLC regarding clinical trial updates for their faridoxorubicin program. It details protocol changes, specifically the removal of a cardiac dosing limit and the path to dose selection. As this is a corporate announcement of operational/clinical progress rather than a full financial report, a legal proceeding, or a specific governance document, it falls under the general regulatory filing category.
2026-02-03 English
FDA Clearance of IND Application for AVA6103
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces that Avacta Group PLC has received FDA clearance for an Investigational New Drug (IND) application. This is a corporate announcement regarding operational/clinical progress rather than a financial report, dividend notice, or governance filing. As it is a standard regulatory announcement of company news, it falls under the RNS category.
2026-01-21 English
Year-end trading update
Regulatory Filings Classification · 95% confidence The document is a 'Year-end trading update' issued by Avacta Group plc. It provides a summary of operational progress, R&D highlights, and financial status for the year ended December 31, 2025. While it contains financial information, it is an initial announcement of performance highlights rather than a full audited annual report (10-K) or a detailed management discussion and analysis (MDA). It follows the standard format of an Earnings Release (ER) or a periodic trading update, which falls under the Earnings Release category in this classification schema.
2026-01-20 English
Appointment of Nominated Adviser & TVR
Regulatory Filings Classification · 97% confidence The document is an RNS (Regulatory News Service) announcement from Avacta Group PLC. It covers multiple topics: the appointment of a new Nominated Adviser, an update on total voting rights, and disclosures regarding a director's past directorships under AIM Rule 17. Since the document contains multiple regulatory updates and does not fit into a single specific category like 'Director's Dealing' or 'Board/Management Information' exclusively, and is distributed via the RNS platform, it is best classified as a general Regulatory Filing.
2026-01-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.